Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia

Boehringer IngelheimBoehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia. Saniona may receive up to €90 million in milestone payments including an upfront payment of €5 million upon signing of the agreement. Furthermore, Saniona is eligible to receive royalties on worldwide net sales of any resulting products under the collaboration.

The joint research activities aim to identify compounds that could be capable of restoring brain network activity in patients with schizophrenia. The neuronal activity in the brain of such patients can be impaired by a functional imbalance between stimulating (excitatory) and inhibitory transmission of signals between neurons.

The program aligns with Boehringer Ingelheim's drug discovery strategy for neuropsychiatric diseases which focuses on systematically investigating dominant symptom domains and the underlying neurobiology across mental disorders such as schizophrenia, Alzheimer’s disease and depression.

"We are very pleased to be working with Saniona's experienced scientific and management team and to build on their ion channel drug discovery platform. Working together and blending our joint expertise and capabilities, we have the potential to advance new treatment options for schizophrenia," says Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim.

Saniona will receive an upfront payment of €5 million upon signing of the agreement and milestone payments of up to €50 million upon the achievement of certain research, development and regulatory milestones. In addition, Saniona is entitled to commercial milestone payments of up to €35 million and tiered royalties on net sales of any potential products commercialised by Boehringer Ingelheim as a result of this collaboration. Further financial details were not disclosed.

"We are delighted to have Boehringer Ingelheim as partner for our schizophrenia program. My team and I have worked in a long lasting partnership with Boehringer Ingelheim before and I can truly say that this is one of our preferred partners. We have a high respect for their diligent and result oriented R&D operations, their company values, and their effective and respectful collaborations with partners," says Jørgen Drejer, CEO of Saniona.

Saniona grants Boehringer Ingelheim exclusive worldwide rights to research, develop, manufacture and commercialise medicines identified through the collaboration. In addition to upfront and milestone payments and royalties on net sales, Saniona will receive undisclosed research funding during the joint research period.

According to the World Health Organisation, mental illness, together with substance abuse disorders remains the leading cause of disability worldwide. In the EU, at least 164 million people (38%) suffer from mental health problems.(1) People with schizophrenia often have problems in many areas of cognition,(2) severely impacting their ability to live or function 'normally'. As a consequence, large numbers of people with schizophrenia are isolated, unemployed and/or homeless.

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.

About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,400 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION.

1. Wittchen HU, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655-79.
2. Sheffield JM, et al. Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn Affect Behav Neurosci. 2014;14:161-74.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...